Hemegenix | Search

Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

24 results for “Hemegenix”

Trials

An Observational Cohort Study to Characterize the Effectiveness and Safety of HEMGENIX® in Patients With Hemophilia B

500 participants · First posted Aug 24, 2023

Drugs

CBR/CMR therapy(Hemogenyx)

BME/AME therapy(Hemogenyx)

BRI2-derived beta amyloid inhibitor (RemeGenix)

Organizations

Hemogenyx Pharmaceuticals LLC

United Kingdom

Hengenix Biotech, Inc.

United States

News

View all 15 →

Karmanos Cancer Institute Becomes First Independent Cancer Center to Offer Hemophilia B Gene Therapy

Nebraska Medicine Administers First Hemgenix Gene Therapy for Hemophilia B

Hemogenyx Pharmaceuticals Advances HEMO-CAR-T Therapy with New Funding and Clinical Trial Approvals

Page 1 of 3